Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
Mridula George, Sadaf Qureshi, Coral Omene, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C. Dueck, Sophie Frantal, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 3, pp. 282-293
Open Access | Times Cited: 173
Computational analysis of protein-ligand interaction by targeting a cell cycle restrainer
Rahul Singh, Rituraj Purohit
Computer Methods and Programs in Biomedicine (2023) Vol. 231, pp. 107367-107367
Closed Access | Times Cited: 54
A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 47
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
Erica L. Mayer, Yue Ren, Nikhil Wagle, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 17, pp. 2050-2060
Closed Access | Times Cited: 41
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
R. Gerosa, Rita De Sanctis, Flavia Jacobs, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104324-104324
Open Access | Times Cited: 20
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Mónica Cejuela Solís, Ana Gil-Torralvo, María Ángeles Castilla, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8488-8488
Open Access | Times Cited: 35
Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
Mikhail V. Blagosklonny
Oncotarget (2023) Vol. 14, Iss. 1, pp. 193-206
Open Access | Times Cited: 34
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
Ciara C. O’Sullivan, Robert Clarke, Matthew P. Goetz, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1273-1273
Open Access | Times Cited: 26
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
Albert Grinshpun, Sara M. Tolaney, Harold J. Burstein, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Senthil Damodaran, Ciara C. O’Sullivan, Ahmed Elkhanany, et al.
Annals of Oncology (2023) Vol. 34, Iss. 12, pp. 1131-1140
Open Access | Times Cited: 25
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2015-2015
Open Access | Times Cited: 23
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
Lu-Qi Cao, Haidong Sun, Yuhao Xie, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition
Alwah R. Al-Ghamdi, Wahid U. Ahmed, Reem I. Al-Wabli, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 833-833
Open Access | Times Cited: 1
Musculoskeletal adverse events associated with CDK4/6 inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database
Zhenlin Chen, Zhiwen Fu, Zhang Nu, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Development and Preclinical Assessment of a Palbociclib Nanostructured Lipid Carrier for Potential Breast Cancer Management
Nida Nehal, Devika Unnithan, Nasr A. Emad, et al.
Molecular Pharmaceutics (2025)
Closed Access | Times Cited: 1
Effect of palliative radiotherapy and cyclin-dependent kinase 4/6 inhibitor on breast cancer cell lines
Marwa Sharaky, Shereen M. El kiki, Heba Effat, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access | Times Cited: 1
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
Ioana-Miruna Stanciu, Andreea Paroşanu, Cristina Orlov‐Slavu, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 987-987
Open Access | Times Cited: 21
HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
Katarzyna J. Jerzak, Nathaniel Bouganim, Christine Brezden‐Masley, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5425-5447
Open Access | Times Cited: 17
Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials
Francisco Cézar Aquino de Moraes, Gustavo de Oliveira Almeida, Vinícius Freire Costa Alves, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 5, pp. 464-464
Open Access | Times Cited: 7
CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug–gene interaction network
Youjun She, Zihan Guo, Qing Zhai, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Functional Genomic Analysis ofCDK4andCDK6Gene Dependency across Human Cancer Cell Lines
Zhouwei Zhang, Lior Golomb, Matthew Meyerson
Cancer Research (2022) Vol. 82, Iss. 11, pp. 2171-2184
Open Access | Times Cited: 26
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
Seth A. Wander, Neil A. O’Brien, Lacey M. Litchfield, et al.
The Oncologist (2022) Vol. 27, Iss. 10, pp. 811-821
Open Access | Times Cited: 26
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Naiba Nabieva, Peter A. Fasching
Cancers (2023) Vol. 15, Iss. 6, pp. 1763-1763
Open Access | Times Cited: 14
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclinD‐CDK4/6 pathway alterations in the DutchDRUPand AustralianMoSTtrials
Laurien J. Zeverijn, Eleonora J. Looze, Subotheni Thavaneswaran, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 7, pp. 1413-1422
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top